Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 98 of 836 for:    Advanced | Neuroendocrine Tumors

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04047251
Recruitment Status : Not yet recruiting
First Posted : August 6, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Fujifilm Pharmaceuticals U.S.A., Inc.

Brief Summary:
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: FF-10850 Topotecan Liposome Injection Phase 1

Detailed Description:

Dose-escalation Phase: Approximately 48 patients are planned for the dose-escalation phase, with at least 6 patients treated at the RP2D.

Cohort Expansion Phase: Four additional cohorts of 12 patients each are planned. Cohort E1: advanced ovarian cancer; Cohort E2: advanced cervical cancer, Cohort E3: advanced sarcomas, and Cohort E4: advanced neuroendocrine tumors including small cell lung cancer. Each cohort will be treated at the RP2D.

In each cohort, FF-10850 will be administered intravenously (IV) until progression of disease, observation of unacceptable AEs, or, after discussion between the Investigator and the Medical Monitor, changes in the patient's condition that prevent further study participation. A sufficient number of cohorts will be enrolled to identify the RP2D.

There will be 3 initial dose levels in this study. FF-10850 will be diluted and infused over 60 minutes.

Approximately 96 patients are planned for the entire trial.

It is anticipated that approximately 4 centers will participate in the dose-escalation phase, with an expansion to approximately 10 centers in the cohort expansion phase. Accrual for the dose-escalation and expansion phases is expected to be approximately 3 years, with patients followed every 3 months from the last dose of study treatment to assess survival.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Open label, dose escalation
Masking: None (Open Label)
Masking Description: None, open label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Ovarian and Cervical Carcinoma, Sarcomas, and Neuroendocrine Tumors Including Small Cell Lung Cancer
Estimated Study Start Date : September 19, 2019
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2025


Arm Intervention/treatment
Experimental: Cohort 1: Treatment at Dose Level 1
FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
Drug: FF-10850 Topotecan Liposome Injection
FF-10850 to be diluted and infused over 60 minutes.

Experimental: Cohort 2: Treatment at Dose Level 2
FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
Drug: FF-10850 Topotecan Liposome Injection
FF-10850 to be diluted and infused over 60 minutes.

Experimental: Cohort 3: Treatment at Dose Level 3
FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
Drug: FF-10850 Topotecan Liposome Injection
FF-10850 to be diluted and infused over 60 minutes.




Primary Outcome Measures :
  1. Determine incidence of Treatment Emergent Adverse Events [ Time Frame: 4 years ]
    Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

  2. Identify dose-limiting toxicities (DLT) of FF-10850 [ Time Frame: 4 years ]
    DLT is defined as any adverse event at least possibly related to FF-10850, and meeting specified DLT criteria

  3. Determine maximun tolerated dose (MTD) of FF-10850 [ Time Frame: 4 years ]
    MTD is defined as the next lower dose of a cohort where patients experienced a DLT

  4. Determine recommended Phase 2 dose (RP2D) FF-10850 [ Time Frame: 4 years ]
    The highest dose level below the dose level eliciting DLT in ≥ 2 patients will be declared the MTD. The RP2D will be chosen based on the MTD or on PK and biological activity if an MTD has not been determined.


Secondary Outcome Measures :
  1. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: Cmax [ Time Frame: 4 years ]
    Measurement of maximum plasma concentration

  2. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: tmax [ Time Frame: 4 years ]
    Measurement of time to reach Cmax

  3. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: t1/2 [ Time Frame: 4 years ]
    Measurement of the elimination half-life

  4. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: AUC [ Time Frame: 4 years ]
    Measurement of the area under the curve of plasma concentration versus time profile

  5. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: MRT [ Time Frame: 4 years ]
    Measurement of the mean residence time adjusted for duration of infusion

  6. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: CL [ Time Frame: 4 years ]
    Measurement of the total plasma clearance

  7. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: Vss [ Time Frame: 4 years ]
    Measurement of the steady-state volume of distribution for total topotecan

  8. Determine objective response rate (ORR) [ Time Frame: 4 years ]
    classified for solid tumors via RECIST v.1.1

  9. Determine the duration of response (DOR) [ Time Frame: 4 years ]
    Duration of Response is calculated from the date of first response to the date of progression or death.

  10. Determine the time to progression (TTP) [ Time Frame: 4 years ]
    Time to progression is calculated from the date of first treatment to the date of first progression

  11. Evaluate progression-free survival (PFS) [ Time Frame: 4 years ]
    Progression-free survival will be calculated from the date of first treatment to the date of progression or death

  12. Evaluate overall survival (OS) (expansion cohorts only) [ Time Frame: 4 years ]
    Overall survival will be calculated from the date of first treatment to the date of death from any cause; patients who do not experience death will be censored at the last follow-up time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet all the following criteria to participate in the study:

  1. Males and females ≥ 18 years of age
  2. Dose-escalation phase: Histologically or cytologically confirmed metastatic and/or unresectable solid tumor, relapsed or refractory to standard therapy, or for which no standard therapy is available that is expected to improve survival by at least 3 months
  3. At least 3 weeks beyond the last chemotherapy (or 3 half-lives, whichever is shorter), radiotherapy, major surgery, or experimental treatment, and recovered from all acute toxicities (≤ Grade 1), prior to the first dose of FF-10850
  4. Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 1
  5. Life expectancy of ≥ 3 months
  6. Adequate hematologic parameters without ongoing transfusion support:

    • Hemoglobin (Hb) ≥ 9 g/dL
    • Absolute neutrophil count (ANC) ≥ 1.0 × 109 cells/L
    • Platelets ≥ 100 × 109 cells/L
  7. Creatinine ≤ 1.5 × ULN, or calculated creatinine clearance ≥ 50 mL/minute by either the Cockcroft-Gault formula or as measured by a 24-hour urine collection
  8. Total bilirubin ≤ 2 × ULN unless due to Gilbert's disease; patients with Gilbert's disease who have a total bilirubin > 6 mg/dL are to be excluded
  9. ALT and AST ≤ 2.5 times ULN, or < 5 × ULN for patients with liver metastases
  10. QT interval corrected for rate (QT interval corrected for rate using Fridericia's Correction Formula, QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening and confirmed pre-treatment on Cycle 1 Day 1.
  11. Patient must be willing to undergo a tumor biopsy, if the patient has a biopsy-accessible tumor

Exclusion Criteria:

  1. Patients who have not received standard/approved therapies expected to improve survival by at least 3 months
  2. History of severe hypersensitivity reactions to topotecan
  3. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or hereditary long QT syndrome
  4. Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care
  5. Active central nervous system (CNS) malignant disease in patients with a history of CNS malignancy. Patients with previously treated stable brain metastases are allowed if they have been stable off steroid therapy for at least 4 weeks.
  6. Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
  7. Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
  8. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
  9. Pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04047251


Contacts
Layout table for location contacts
Contact: FPHU Study Coordinator fphucontact@fujifilm.com

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute (DFCI) Not yet recruiting
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Fujifilm Pharmaceuticals U.S.A., Inc.

Layout table for additonal information
Responsible Party: Fujifilm Pharmaceuticals U.S.A., Inc.
ClinicalTrials.gov Identifier: NCT04047251     History of Changes
Other Study ID Numbers: FF10850US101
First Posted: August 6, 2019    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Topotecan
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents